SCHEMBL1976945

SCHEMBL1976945

COc1ccc(C=Cc2ccc(O)cc2)c(OC)c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 13/20 0.81
CYP1A1 P04798 13/20 0.81
CYP1B1 Q16678 13/20 0.81
NFE2L2 Q16236 2/20 0.81
MAPT P10636 2/20 0.79
APP P05067 1/20 0.79
CYP19A1 P11511 1/20 0.72
BACE1 P56817 1/20 0.71
CYP3A4 P08684 2/20 0.69
CYP2C19 P33261 2/20 0.69
CYP2E1 P05181 1/20 0.69
CYP2C8 P10632 1/20 0.69
CYP2D6 P10635 1/20 0.69
CYP2A6 P11509 1/20 0.69
CYP2C9 P11712 1/20 0.69
CYP4B1 P13584 1/20 0.69
CYP2B6 P20813 1/20 0.69
CYP3A5 P20815 1/20 0.69
CYP2A7 P20853 1/20 0.69
CYP3A7 P24462 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Resveratrol SCHEMBL9273945 0.92 CYP1A1 (0.76) CYP1A2CYP1A1CYP1B1NFE2L2MAPT
SCHEMBL5495431 0.90 CYP1A2 (1.00) CYP1A2CYP1A1CYP1B1NFE2L2MAPT
SCHEMBL5495428 0.90 CYP1A2 (1.00) CYP1A2CYP1A1CYP1B1NFE2L2MAPT
SCHEMBL10167885 0.88 APP (1.00) CYP1A2CYP1A1CYP1B1NFE2L2MAPT
SCHEMBL1607405 0.88 APP (1.00) CYP1A2CYP1A1CYP1B1NFE2L2MAPT
SCHEMBL1603801 0.88 APP (0.87) CYP1A2CYP1A1CYP1B1NFE2L2MAPT
SCHEMBL1603799 0.88 APP (0.87) CYP1A2CYP1A1CYP1B1NFE2L2MAPT
SCHEMBL13191839 0.88 APP (1.00) CYP1A2CYP1A1CYP1B1NFE2L2MAPT
SCHEMBL29373798 0.88 APP (1.00) CYP1A2CYP1A1CYP1B1NFE2L2MAPT
SCHEMBL28360809 0.86 CAPN1 (0.85) CYP1A2CYP1A1CYP1B1NFE2L2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524782-B2 Key intermediate for the preparation of Stilbenes, solid forms of Pterostilbene, and methods for making the same LAURUS LABS PRIVATE LIMITED (IN) 2013-09-03 US claimed
US-8524782-B2 Key intermediate for the preparation of Stilbenes, solid forms of Pterostilbene, and methods for making the same LAURUS LABS PRIVATE LIMITED (IN) 2013-09-03 US disclosed
US-20110144212-A1 KEY INTERMEDIATE FOR THE PREPARATION OF STILBENES, SOLID FORMS OF PTEROSTILBENE, AND METHODS FOR MAKING THE SAME APTUIT LAURUS PRIVATE LIMITED (IN) 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144212-A1 KEY INTERMEDIATE FOR THE PREPARATION OF STILBENES, SOLID FORMS OF PTEROSTILBENE, AND METHODS FOR MAKING THE SAME SIRT5, SQLE, PDHB CYP1A2 1950/4885CYP1A1 1795/4885CYP1B1 983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.